SCHEMBL6374241

SCHEMBL6374241

CCC(O)Nc1cccc2c1C(=O)c1cccc(NC(O)CC)c1C2=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.53
▸ EGFR P00533 2/20 0.53
▸ MAPK1 P28482 2/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ L3MBTL1 Q9Y468 2/20 0.53
▸ PABPC1 P11940 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ MAOA P21397 2/20 0.51
▸ TERT O14746 10/20 0.47
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ POLB P06746 2/20 0.46
▸ RAD52 P43351 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ DNMT1 P26358 1/20 0.46
▸ SMARCA2 P51531 1/20 0.46
▸ NSD2 O96028 1/20 0.43
▸ FGB P02675 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6370945 0.87 MAPT (0.50) MAPTEGFRMAPK1SMN1; SMN2L3MBTL1
SCHEMBL4956713 0.81 MAPT (0.34) MAPTEGFRMAPK1SMN1; SMN2L3MBTL1
SCHEMBL6366561 0.81 MAPT (0.58) MAPTEGFRMAPK1SMN1; SMN2L3MBTL1
SCHEMBL8034804 0.80 MAPT (0.62) MAPTEGFRMAPK1SMN1; SMN2L3MBTL1
SCHEMBL8639310 0.79 MAPT (0.60) MAPTEGFRMAPK1SMN1; SMN2L3MBTL1
SCHEMBL6663870 0.78 MAPT (0.55) MAPTEGFRMAPK1SMN1; SMN2L3MBTL1
SCHEMBL6659442 0.78 MAPT (0.55) MAPTEGFRMAPK1SMN1; SMN2L3MBTL1
SCHEMBL4732620 0.78 MAPT (0.64) MAPTEGFRMAPK1SMN1; SMN2L3MBTL1
SCHEMBL126130 0.78 MAPT (0.58) MAPTEGFRMAPK1SMN1; SMN2L3MBTL1
SCHEMBL5605703 0.77 MAPT (0.61) MAPTEGFRMAPK1SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009924-A1 Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives HUANG HSU-SHAN (TW) 2005-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009924-A1 Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives NFE2L2, NR2F2, TFAM MAPT 4766/4885EGFR 3160/4885MAPK1 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback